期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 19, 期 5, 页码 641-652出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543781003767400
关键词
-
资金
- Deutsche Krebshilfe [10-1507H, 106430]
- Faculty of Clinical Medicine Mannheim, University of Heidelberg
- Alfried Krupp von Bohlen und Halbach Foundation
- Wilhelm Sander Stiftung
- Auguste-Schaedel-Dantscher-Stiftung
- Ingrid zu Solms Foundation
- Dr Hella-Buehler-Foundation
- European Union [LSHB-CT2003-503410, 2005105]
Areas covered in this review: Several therapeutic strategies inhibiting the uPA system have been or are currently being developed for suppression of tumor growth. This review examines the role of the uPA system in tumor progression and assesses the various therapeutic strategies developed to selectively exploit this system. What will the reader gain: We focus on the therapeutic developments of the last 15 years. In addition to antibodies and recombinant uPA- or uPAR-derived proteins, various antagonistic peptides as well as small molecules have been designed and synthesized that inhibit the uPA system, leading to reduced tumor progression. Take home message: The multifunctional potential of the uPA system in cancer has rendered this system an attractive novel target for anticancer therapy. A few novel tumor biology-based therapeutic strategies reported here, opening new ways for patient-optimized and individualized cancer therapy. It may be the right time to evaluate the hypothesis that the uPA system plays a pivotal role in cancer progression and that targeting this system will lead to clinical benefit in cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据